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ABSTRACT 
 
Cannabidiol (CBD), a once-considered inert cannabis constituent, is one of two primary 
constituents of cannabis, alongside delta-9-tetrahydrocannabinol (∆9-THC/THC). In the 
last 30 years, CBD has become implicated with a range of pharmaceutical mechanisms 
of great therapeutic interest and utility. This review details the literature speculating 
CBD’s attenuation of psychotic symptoms, particularly in light of a marked elevation in 
mean THC concentrations, and a concomitant decline in CBD concentrations in the 
prevalent U.K street market cannabis derivatives since c. 2000. CBD is purported to 
exhibit pharmacology akin to established atypical antipsychotics, whilst THC has been 
implicated with the precipitation of psychosis, and the induction of associated symptoms. 
The aim of the review was to clarify the conjecture surrounding CBD’s antipsychotic 
efficacy, before going on to detail prominent theories about its associated 
pharmacodynamics. Were CBD’s antipsychotic efficacy established, then there is 
potential for major latent anthropological repercussions to manifest, such as significant 
elevations in psychosis manifestations in the U.K. The review found a largely affirmative 
body of evidence asserting CBD’s antipsychotic efficacy. CBD exhibited capacity to 
attenuate natural and artificially induced psychoses in both animal and human cohorts, 
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the latter of which included individuals considered resistant to conventional treatment. 
CBD also shows promising potential for use as an antipsychotic drug for Parkinson’s 
disease (PD) patients with psychosis, owing to its low rate of extra-pyramidal side-effect 
induction. A range of potential pharmacological mechanisms behind CBD’s neuroleptic 
pharmacology are outlined, with particular emphasis on its prevention of the hydrolysis 
and reuptake of the endogenous cannabinoid, anandamide. However, given the nebular 
aetiological basis for psychoses, explicit conclusions on how CBD attenuates psychotic 
symptoms remains to be determined. 
 
 
Keywords: Cannabidiol; CBD; antipsychotic; THC; psychosis; schizophrenia; anandamide; 
cannabinoid. 
 
1.INTRODUCTION 
 
Cannabidiol (CBD) is one the constituents of Cannabis. Although the research looking into 
the antipsychotic efficacy of CBD has increased in the last decade, there’s still a necessity 
for more to be done. The literature is not overwhelmingly in support of the postulation, and 
our lack of knowledge about cannabinoids, the endogenous cannabinoid system, and their 
interaction, renders our knowledge of neurophysiology, psychopharmacology, and 
psychiatric therapeutics, as severely deficient. As such, this review seeks to not only serve 
as a tool for demystifying the stigma which surrounds Cannabis amongst laymen and 
scholars alike, but also as a comprehensive and largely chronological reference text for 
anyone who’s already established, or interested in furthering their erudition, in the field of 
cannabinoids, the endocannabinoid system, cannabidiol, and the development of psychiatric 
therapeutics. Although preceding reviews have provided invaluable insight and clarity to the 
question of CBD’s antipsychotic efficacy, this review expounds on salient points which 
previous papers have failed to be address. 
 
2. CANNABIS’ HISTORICAL CONTEXT 
 
The antiquity of Hemp utilisation purportedly traces back c.10,000 B.C. to south-eastern 
regions of Taiwan, where evidence of its use in rope manufacture has been documented, 
prior to its significant incorporation as one of the five major “grains” in Neolithic Chinese 
civilisations, in spite of its technical classification as a nut [1-3].Over the succeeding 
centuries Cannabis utility permeated westwards, through India into the middle-east, 
becoming established in Asia as a significant ceremonial and medicinal plant for centuries 
from c.650 B.C, and acknowledged by the likes of Avicinna (Ibn Sīnā) in his magnum opus, 
Canon of Medicine (c. 1000 A.D.) [4]. 
 
Hemp’s introduction to western medicine is largely accredited to W.B. O'Shaughnessy, who 
published his discoveries of the plant’s therapeutic- sedative, appetite stimulant, anxiolytic, 
antiemetic, analgesic, and anticonvulsive- properties, in 1843 [5]. His publication concluded 
with the conviction that “we possess no remedy at all equal to this in anti-convulsive and 
anti-neuralgic power”. 
 
By the turn of the 20th century, the production and prescription of hemp extracts and 
tinctures were common for ailments ranging from pains, whooping cough, and asthma, 
however this swiftly and almost completely stopped by the middle of the century; primarily 
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due to the interdiction of Cannabis in the west, but also owing to variability in effects, extract 
potency, and introduction of more stable synthetic pharmaceutical substitutes [6]. 
 
3. CANNABIS AS A SOURCE OF EXOGENOUS PHYTOCANNABINOIDS 
 
Cannabis is a genus of the Cannabaceae family, with the most pertinent species with regard 
to recreational, medical, and research utility being Cannabis sativa and Cannabis indica, of 
which the former is capable of growing in both temperate and tropical climates [7-8]. More 
than 60 of the known 460 chemicals within Cannabis are classified as phytocannabinoids- as 
light is a requisite for their synthesis- which, following the isolation and identification of 
naturally occurring endogenous (endo)cannabinoids and their respective receptors in 1999, 
greatly piqued the research community’s interest towards the exogenous light-synthesised 
(phyto)cannabinoids of Cannabis [9-10]. Glandular trichomesprotruding from the stem and 
leaves of the Cannabis plant are the primary, if not sole, site of Hemp’s cannabinoid 
biosynthesis; the principle constituents being considered to be ∆9-tetrahydrocannabinol 
(THC) and cannabidiol (CBD), which are synthesised in accordance to genetically 
determined ratios [11-12]. 
 
3.1 Delta-9-Tetrahydrocannabinol (THC) 
 
Since its isolation by Gaoni and Mechoulam in 1964, Delta-9-Tetrahydrocannabinol (∆9-
THC/THC), a phytocannabinoid which exhibits a mechanism of action, and receptor affinity, 
ostensibly analogous to that of the endocannabinoid anandamide (albeit with a lesser affinity 
for CB1 and lower still for CB2 receptors), was long attributed to be the primary compound 
responsible for the therapeutic and intoxicating psychotomimetic effects of Cannabis- 
principally due to its partial agonism (Ki value in the low nanomolar range) of the G-protein 
coupled cannabinoid receptors (CBR) CB1R and CB2R [8,13-15]. Although under the 
influence of a multitude of variables- environment, subjective mindset, personality, and 
tolerance- THC’s effects are considered biphasic, in that low doses induces analgesic, 
euphoric, sedative/hypnotic, antidepressant, anxiolytic, and myorelaxant properties amongst 
others, while numerous of the effects which are considered unfavourable, such as cognitive 
impairment, anxiety, depersonalisation, and perceptual distortion, manifest as a result of its 
high or rapid dosage administration [8,12,16]. 
 
3.2 Cannabidiol (CBD) 
 
CBD- first isolated in 1940, prior to its subsequent structural elucidation in 1963- is the 
predominant cannabinoid constituent in Cannabis varieties typically cultivated for fibre and 
edible oils, resulting in a stockier stem and taller plan; there is generally less psychotropic 
THC synthesised in these varieties comparative to those grown for recreational use [17-19]. 
In spite of having been identified more than two centuries prior to THC, CBD has received 
comparatively limited attention from the scientific research community; the paucity of 
research interest towards CBD is arguably, in part, the result of early studies, which 
suggested CBD had a lack of cannabinoid (CB) receptor affinity, and as such potentially inert 
or insignificant pharmacology [9,20-21]. Since the turn of the millennium the field of CBD 
research gained momentum as a plethora therapeutic effects were discovered, including 
anxiolytic, neuroprotective, sedative/hypnotic, antiemetic, anti-arthritic, anti-inflammatory, 
and antipsychotic effects [8-9,12,22-30] (for an extensive outline of the ostensible 
pharmacological effects and underlying pharmacodynamics the reader is referred to the 
articles of Pertwee [15] and Izzo [27]).This review is principally focused on assessing the 
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research literature which has emerged concerning CBD’s ostensible antipsychotic 
pharmacology and its potential development as a psychiatric therapeutic, in addition to the 
postulated underlying pharmacokinetic mechanisms behind it. 
 
4. CANNABIS & PSYCHOSIS 
 
The interest in cannabidiol’s antipsychotic efficacy lies partly in Cannabis’ early association 
with psychosis. Kurt Beringer- accredited to the conception of the term ‘model psychosis’- 
proposed, in the first systematic study to utilise defined dosages, that the effects of Cannabis 
induced psychopathological alterations analogous to psychoses such as schizophrenia [31]. 
Subsequently, studies into the psychotomimetic properties of Cannabis and its professed 
causal link with the manifestation of psychoses- largely attributed to the action of THC 
following its isolation, owing to its explicit CB receptor agonism- lead to apprehension of its 
utility; this is still a disputed field of research however. Some studies have asserted a link 
between Cannabis use and induction of psychoses; one study has asserted a two-fold 
increase in the risk of schizophrenia manifestation as a result of frequent use [32]. On the 
other hand Frisher’s [33] study into schizophrenia manifestations in the U.K between the 
years 1996 and 2005 found no evidence of elevated schizophrenia and psychosis rates. The 
study investigated the years 1996 to 2005, giving 3 reasons for this: (1) frequent Cannabis 
use increases relative risk of schizophrenia manifestation by 1.8 - 3.1; (2) considerable 
increase in U.K. Cannabis use from the mid-1970s; and (3) elevated risk of schizophrenia 
manifestation for 20 years from first use. 
 
If CBD’s antipsychotic efficacy was to be affirmed, then it would lead to justifiable scrutiny of 
Frisher’s [33] chosen years of analysis, for studies have asserted that the U.K street market 
was predominantly saturated with Cannabis containing on average substantially higher 
concentration of CBD prior to 2000, before being principally replaced by high THC, low CBD, 
Cannabis of the sinsemilla variety (Table 1) [11, 34]. This may not only explain the largely 
torpid, and at times declining, incidences of schizophrenia and psychosis in the scrutinised 
years, but it may also allow us to anticipate marked elevation in incidences of psychosis 
between the years 2020-2030, if Frisher’s [33] third assertion is proved to be correct. 
 
5. THE ENDOGENOUS (ENDO)-CANNABINOID SYSTEM 
 
The retrograde Cannabinoid signalling system is considered to comprise of the cannabinoid 
CB1 and CB2 receptors, the endogenously synthesised (endo)-cannabinoid ligands, and 
endocannabinoid biosynthesis/inactivation mechanisms [27]. The Cannabinoid CB1 and 
CB2 receptors- which fall under the super-family of G-protein-coupled receptors- were 
identified and cloned in the early 1990s, and comprises a large portion of human 
neurological pathways, being expressed in the brain at a higher prevalence than all the 
dopamine, noradrenaline and serotonin receptors combined, while being up to ten times 
more prevalent than opioid receptors [16,35-36]. The distribution of the cannabinoid receptor 
sub-types were subsequently elucidated, with CB1 receptors having been identified as 
located primarily in central and peripheral neurones while being expressed, though to a 
lesser degree, in non-neuronal cells like immune cells; CB2 receptors were found to be 
prevalent in immune cells, though they’re also present and expressed in neuronal cells of the 
central nervous system [15,37-40].  
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Table 1. The mean THC:CBD concentrations (%) of the U.K street market Cannabis 
derivatives in 2004/5, their historic prevalence, method of production and cultivation. 
Information has been taken and adapted from [11,34] 
 
Cannabis 
Variety 
Method of Production 
and Cultivation 
Mean 
THC:CBD 
content in the 
U.K street 
market as of 
2004/5 (%) 
Prevalence and 
Availability in the U.K 
Hashish Comprised entirely by the 
compression of the 
Cannabis’ trichomes, 
which forms a malleable, 
often black, solid 
derivative. 
3.54 : 4.17 Comprised approximately 
70% of the ‘street market’ 
up until c.2000, hashish 
has subsequently become 
the least readily available 
Cannabis derivative. This 
reduction in CBD rich 
Cannabis availability has 
potential implications to 
the welfare of smokers, if 
its antipsychotic effect is 
acknowledged 
Herbal 
Marijuana 
Often grown and imported 
from tropical or sub-
tropical countries. The 
outdoor grown, pollinated 
female plants are 
compressed and contain 
the foliar and floral 
material. 
2.14 : <0.10 Prevalence has increased 
since c.2000s, though at a 
much lower rate than 
sinsemilla 
Herbal 
Sinsemilla 
(Spanish 
derivation 
meaning 
seedless)- 
commonly 
termed 
‘skunk’ 
Predominantly grown 
indoors in countries where 
it is illegality and 
unsuitable weather 
prevents out-door 
production, as is the case 
for the U.K. The crop is 
all-female so as to inhibit 
seed production and to 
maximise cannabinoid 
production and yield. 
Specialised technical 
equipment is used to 
maximise growth- these 
selectively bred varieties 
are harvested for their 
glowering buds and their 
disproportionately high 
THC content. 
13.98 : <0.10 As of c.2000 sinsemilla 
has become the most 
available Cannabis 
variety, potentially 
comprising of more than 
70% of the U.K street 
market, whereas it was 
the least predominant 
prior to c.2000. Given 
THC’s implication with 
precipitated psychosis, 
juxtaposed with CBD’s 
ostensible antipsychotic 
efficacy, then the drastic 
increase in sinsemilla 
prevalence has the 
potential to result in 
serious implications to the 
psychological welfare of 
U.K Cannabis smokers 
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N-arachidonoylethanolamine (anandamide- from the Sanskirt word ananda, or ‘bliss’) and 2-
arachidonoylglycerol (2AG), were the first two endogenously synthesised 
(endo)cannabinoids to be discovered; they were revealed to be capable of agonising both 
the identified cannabinoid CB1 and CB2 receptor sub-groups, while their synthesis was 
found to take place in response to elevations in intracellular calcium concentrations [15,41-
45].It is generally accepted that CB1 is responsible for retrograde regulatory inhibition of 
neurotransmitters such as glutamate and GABA, following endocannabinoid (namely 
anandamide and 2AG) biosynthesis, release, and agonism, subsequent to postsynaptic 
intracellular calcium increases induced by certain neurotransmitter stimulation- this 
presynaptic neuron activation by ligands released from the postsynaptic cleft is termed 
retrograde signalling (Reader is advised to refer to the figure within Ashton’s paper [16]). 
CB2 is considered responsible for the mediation of messenger release, such as cytokines in 
immune cells, as well as potential modulation of immune cell migration within and outside 
the central nervous system [15-16,46]. 
 
As such, the endocannabinoid system seemingly acts as a form of modulatory system, 
functioning to attenuate the potential to be overwhelmed by excitatory or inhibitory neuronal 
activity. Because of its regulatory action to the activity of other neurotransmitter systems- 
particularly glutamate and GABA, but also serotonin- postulations as to its dysfunctions 
inducing states of neuropsychological extremes typical in psychosis have been conceived- 
mania and hyperarousal at one end, juxtaposed with anhedonia and depression at the other 
[47-51]. 
 
This is supported by research implicating the glutamatergic and GABAergic neurotransmitter 
systems with states of psychoses; given the dopamine antagonism exhibited by conventional 
antipsychotics, current literature has greatly appealed to the notion of a dysfunctioning 
dopaminergic signalling pathway, and as such the thesis of cannabinoid-dopaminergic signal 
pathway interaction is of particular significance [47,52-54]. A lack of a direct cannabinoid 
system interaction with dopaminergic signalling pathways is plausible, due to little evidence 
for CB1 receptor presence on dopaminergic neurones in the basal ganglia and limbic 
system, though studies have revealed increased meso-prefrontal dopaminergic activity in 
conjunction with dopamine neurone excitation in the ventral tegmentum and substantia nigra 
consequent to cannabinoid administration- perhaps this is the result of GABAergic and 
glutamatergic activation and interaction with the dopaminergic signalling pathway, the latter 
of which is considered in a recent analysis of cannabinoid-dopaminergic pathway interaction 
[47,55-59]. Thus, seeing as the aforementioned neurological pathways have been implicated 
with the manifestation of artificial and naturally occurring states of psychosis (in both human 
and animal subjects) a necessity for the elucidation of the elaborate conjecture surrounding 
the constituents of the endocannabinoid system is warranted- particularly in light of its role in 
neuronal signal modulation [9,49,52,60-61]. 
 
6.  ENDOCANNABINOID SYSTEM INTERRACTION WITH EXOGENOUS 
CANNABINOIDS 
 
It has been posited that the presence of CBD, and the other trace cannabinoids(in 
conjunction with the primary psychotropic substance, THC), produces somewhat of a refined 
‘entourage effect’, making for synergistic activity in Cannabis extracts that is absent in 
isolated CBD or THC administration- a thesis which is supported by studies suggesting that  
the effects of Cannabis extracts are up to four times greater intensity in one study on 
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animals & humans, and 330% greater in another done on mice alone, than that expected of 
their known THC content [12,62-64].  
 
Anandamide, the endogenous cannabinoid which exhibits a mode of action analogous to 
that of THC, has of late been identified as a potential indicator for psychosis manifestation 
following its eight-fold elevation in the cerebrospinal fluids of subjects who were treated with 
atypical antipsychotics or were antipsychotic-naive; this elevation was absent in healthy 
volunteers and those treated with typical antipsychotics [13,24]. This gives rise to conjecture 
as to the potential role of anandamide as an innate biological response to psychosis 
manifestation, perhaps as a form of natural antipsychotic, working to attenuate its 
manifestation. This research has further implications to the scrutiny of CBD’s antipsychotic 
efficacy, in light of studies reporting its role in preventing anandamide hydrolysis (by fatty 
acid amide hydrolase (FAAH)), and reuptake [22,65-66]. Furthermore, CBD has been found 
to elevate blood and brain THC levels, whilst exhibiting an inhibitory effect on THC 
metabolism, reducing the presence of its metabolite (THC-COOH and 11-OH-THC) 
subsequent to CBD pretreatment [65-66]. Thus, in light of research having established 
antagonistic properties of CBD to CB receptor agonists, in conjunction with its 
aforementioned modulations of anandamide, THC, glutamatergic, and GABAergic signalling 
pathways, one can appreciate that the effect of the cannabinoid system on states of 
psychosis is very much convoluted, interrelated and in need of elucidation- apt given the 
abundance of aetiological postulations for psychoses [22,29,47,65-66]. Consequently, our 
knowledge of pharmacology, neurophysiology, and psychiatric disorders, are severely 
impeded and in need of explication, considering the wide spread influence (and our severely 
deficient understanding of the role and impact) of the endocannabinoid system. 
 
7.  PARADIGMS CONCERNING THE STUDIES LOOKING INTO 
CANNABIDIOL’S ANTIPSYCHOTIC EFFICACY 
 
7.1 Neurochemical Hypotheses and Induction of Psychosis in Test Subjects 
 
Tests exploring the antipsychotic efficacy of Cannabidiol utilise either human models hitherto 
afflicted with psychoses or humans/animals artificially with artificially induced psychosis 
following exposure to psychotomimetic substances, which are believed to emulate a certain 
component of the hypothesised aetiological, and pathophysiological, dysfunction of 
psychiatric disorders, in accordance with relevant neurochemical hypotheses [49,52,60-61]. 
 
7.2 Dopaminergic Induction of Psychosis 
 
Schizophrenia has been strongly implicated with a dysfunctioning (overactive) dopaminergic 
signalling pathway, the notion of which is supported by the fact that modern (typical) 
antipsychotics- which attenuate symptomatic behaviours such as attention & cognitive 
deficits, social withdrawal, and hyperlocomotion subsequent to administration- are 
predominantly dopamine D2 receptor antagonists [58,60,67].Thus dopamine D2 agonists 
like apomorphine and amphetamines are used as psychotomimetics to artificially induce 
dopaminergic psychosis- resulting in the manifestation of stereotyped behaviours indicative 
of a state of psychosis- by stimulating dopamine release, whilst inhibiting the dopamine 
transporters’ capacity for reuptake [6].Accordingly, the dopaminergic theory of schizophrenia 
is considered one of two principle models employed studies which seek to induce artificial 
states of psychosis in healthy human and murine models.  
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7.3 Glutamatergicmodels of Psychosis 
 
Dysfunctional glutamatergic neurotransmission is the second significant postulated 
neurochemical hypothesis for psychosis. This is supported by studies showing that 
schizophrenic patient sexhibit deficits in glutamatergic neurotransmission, which is further 
validated by the attenuative efficacy of atypical antipsychotic like clozapine, which primarily 
exhibit glutamate N-methyl-D-aspartate (NMDA) receptor agonism, but also loose, transient 
interaction with acetylcholine, histamine, serotonin, and dopamine pathways [6,60-61,67-68]. 
This explains the use of NMDA receptor antagonists- such as, MK-801, and ketamine (or its 
related compound, phencyclidine) – as psychotomimetics for the induction and study of 
artificially induced glutamate-associated psychosis [6,49,68-69]. 
 
7.4 Flaws in Contemporary Antipsychotics 
 
The antipsychotic efficacy of a neuroleptic/antipsychotic drug is largely gauged by the 
degree to which it is capable of attenuating the stereotyped, psychosis-associated, 
behavioural symptoms in either natural or artificially induced states of psychosis. 
 
The use of typical antipsychotics are particularly effective in the attenuation of ‘positive’ 
psychotic symptoms, such as agitation, delusions, and hallucinations; they are however 
generally ineffective- and at times augmentative- to ‘negative’ symptoms of chronic 
psychosis, which include impaired cognition manifested as alogia, deficient working memory, 
social withdrawal, and apathy [67]. 
 
Furthermore, owing to the dopaminergic antagonism of typical antipsychotics, patients are 
often at risk of hyperprolactinaemia; the disruption to prolactin’s secretory regulation is due 
to a resulting lack of dopamine release from the hypothalamic arcuate nucleus, which 
prevents its usual tonic inhibition of the anterior-pituitary mammotrophic cells [6,67]. 
 
Moreover, Typical antipsychotics are associated with a high risk, even at low concentrations, 
of extrapyramidal side-effects, ranging from (tardive) dyskinesia, to dystonia and akathisia; 
the severity of these side-effects are dose-dependent, and as such the use of neuroleptic on 
Parkinson’s patients are problematic [70-71]. 
 
Atypical antipsychotics on the other hand have shown a capacity to attenuate the psychotic 
behaviours and hyperlocomotion induced by artificial psychosis models, not only at lower 
doses than typical antipsychotics, but also with lower incidences of both extrapyramidal and 
prolactin side-effects; speculatively this is the result of their comparatively lower dopamine 
D2 affinity, juxtaposed with serotonin 5-HT2A receptors affinity [6,67]. 
 
Having said this, one can understand why research suggesting that CBD possesses a 
pharmacological profile akin to modern atypical antipsychotics galvanised the literature 
assessing the legitimacy of the assertions, and the underlying mechanisms of action 
underpinning its pharmacology. Prominent pre-clinical and clinical studies regarding CBD’s 
antipsychotic pharmacology, their study designs, and significant assertions, are 
consequently detailed, prior to a summation of the prominent pharmacokinetic theories, so 
as to form a concise, mostly chronological, narrative of the fields’ progression.  
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8.  PRECLINICAL INVESTIGATIONS INTO THE ANTIPSYCHOTIC EFFICACY 
OF CBD USING RODENT MODELS OF MANIA 
 
Speculation into cannabidiol’s antipsychotic properties first emerged in 1982, when, in an 
interactive study involving healthy volunteers, CBD displayed attenuating capacity against 
THC-induced stereotyped behaviours associated with states of psychosis- namely 
disturbance of perceptions, disconnection of thought, depersonalisation, and resistance to 
communication [72]. Support emerged later that year in a study observing Cannabis users 
admitted into a psychiatric hospital in South Africa, which reported a significantly high 
frequency of acute psychotic symptoms in patients who had used Cannabis devoid of 
cannabidiol [9,73]. 
 
Research into cannabidiol’s neuroleptic potential subsequently underwent a state of torpor 
for nearly a century, until a study comparing its effects to the established typical 
antipsychotic Haloperidol, wherein rat models with dopamine-associated psychosis induced 
by apomorphine administration were utilised [74]. Murine models of psychosis are typically 
assessed in accordance with stereotypical behaviours considered indicative of a psychotic 
state, such as vulnerability to stress in the form of stress-induced hyperlocomotion, 
increased biting and sniffing, attentional and cognitive deficits which impair performance in 
tests, and social withdrawal [9,60]. Both CBD (60 mg/kg) and haloperidol (0.5 mg/kg) were 
shown to dose-dependently reduce the stereotyped behaviours induced by the dopamine 
agonistic apomorphine [74]. Furthermore, an elevation in the serum prolactin resulted 
subsequent to both haloperidol (0.125, 0.25, 0.5 mg/kg) and CBD (240 mg/kg) 
administration. Even at doses as high as 480mg/kg CBD did not induce a cataleptic 
response in the rats; unlike haloperidol, which did so at doses as low as 0.25 mg/kg.  
 
This was further supported by a study by Moreira [75], which utilised both dopamineric and 
glutamatergic animal (mice) models of psychosis- induced by amphetamine and sub-
anaesthetic doses of ketamine administration, respectively- in a study assessing 
cannabidiol’s (15, 30, 60 mg/kg) efficacy in inhibiting the consequently induced 
hyperlocomotion, compared to haloperidol (0.15, 0.3, 0.6 mg/kg) and the atypical 
antipsychotic clozapine (1.25, 2.5, 5.0 mg/kg). The study employed the catalepsy test so as 
to assess clozapine, haloperidol, and CBD’s potency of catalepsy induction. The severity of 
the induced catalepsy is used as an indicator of the drug’s probability of inducing extra-
pyramidal side-effects in human subjects; the test involves recording the time a mouse 
remains stagnant with its paw on a horizontal bar after having it placed there [76]. 
Cannabidiol, unlike clozapine and haloperidol, produced neither detrimental cataleptic or 
sedative effects. Furthermore, 30 minutes subsequent to an injection of the psychotomimetic 
amphetamine/ketamine, the distance travelled by the mice was measured for a 10 minute 
period; it was found that both cannabidiol (30, 50 mg/kg) and clozapine (5 mg/kg) showed 
effectiveness at inhibiting stress-related hyperlocomotion in the mice, whereas haloperidol 
did not [75]. 
 
A year later Long [77] conducted a study to test the neuroleptic capacity of both CBD (5 
mg/kg) and clozapine (4 mg/kg) on glutamatergic MK-801-induced psychosis in mice, and 
found that both substances proved capable of attenuating the models’ MK-801-induced pre-
pulse inhibition (PPI) disruption- a functional gauge of sensorimotor gating which has been 
shown to be impaired in patients with schizophrenia [78-79]. 
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Malone [80] sought to evaluate the effects of both THC and CBD administration on the social 
interaction of Sprague-Dawley rats and found that cannabidiol and THC- when administered 
in isolation- induced no effect and reduced social interaction, respectively. As such the study 
looked at the effect of cannabidiol (20 mg/kg) pre-treatment prior to THC (1 mg/kg) 
administration, and found that the pre-treatment induced an attenuating affect to the social 
withdrawal induced by the latter, enforcing the postulated antipsychotic effect of CBD. 
 
In a study consisting of two experiments- the first of which comprised of two treatment 
paradigms- Valvassori [81] looked into the effects of CBD on dexamphetamine-induced 
oxidative stress in rats. The first experiment’s primary paradigm- termed ‘reversal treatment’- 
involved the daily intraperitoneal administration of saline or the psychotomimetic 
dexamphetamine (2mg/kg) for 14 days, with twice daily injections of saline or CBD (15, 30, 
60 mg/kg) from days 8 to 14. The secondary ‘prevention treatment’ paradigm involved twice 
daily intraperitoneal injections of saline or CBD, with daily injections of saline or 
dexamphetamine from days 8 to 14. The second experiment scrutinised CBD’s (30 & 60 
mg/kg) capacity to thwart dexamphetamine-induced carbonyl group formation in the 
prefrontal cortex. Despite finding that CBD was successfully able to increase brain-derived 
neurotrophic factor (BDNF) expression, while lessening the dexamphetamine-induced 
oxidative protein damage in the striatum and hippocampus, Valvassori [81] reported that 
CBD had no attenuative effect to the hyperlocomotion induced by dexamphetamine in either 
of the two experiments. As such this study brings into contention not only CBD’s neuroleptic 
legitimacy, but also the hypothesis that CBD’s antioxidant and neuroprotective capacity may 
possibly be behind its antipsychotic efficacy [82]. 
 
Long [83] set out to investigate, amongst others, the effect that acute (1, 5, 10, 50 mg/kg) 
and chronic (1, 5, 10, 50 mg/kg; over 8 weeks) CBD exposure would have on the 
dexamphetamine-induced hyperlocomotion and PPI test paradigms in C57BL/6jArc mice. 
Positive and significant increases in the PPI of the mice was reported as a result of both 
acute (1, 5, 50 mg/kg) and chronic (1 mg/kg at 18) CBD administration. On the other hand, 
only chronic administration of CBD (50 mg/kg) showed a capacity to attenuate 
dexamphetamine (5 mg/kg)-induced hyperlocomotion, suggesting that CBD exhibits 
antagonism to substances which induced psychotic symptoms subsequent to long term 
exposure, despite Moreira [75] having reported successful attenuation of amphetamine-
induced hyperlocomotion by acute CBD administration. Zuardi [82] explicate that this 
discrepancy could have arisen from differences in drugs used to induce stereotyped 
behaviours, rodent strains, and administration regimes. 
 
In a pioneering study Klein [66] looked into cannabidiol’s potentiation of THC 
pharmacodynamics and psychotomimetic properties in adolescent rats, finding evidence 
conflicting with research suggesting that CBD possesses antipsychotic activity. Cannabidiol 
was not only found to exacerbated the social withdrawal and anxiogenic effects induced in 
rats administered with THC, but it also served to augment the blood and brain THC levels, 
while lowering the concentrations of its metabolites, 11-OH-THC (which exhibits similar 
pharmacological activity) and the non-psychoactive THC-COOH. Interestingly a 
previousstudy had recognised CBD’s augmentative effects on THC, so long as CBD 
administration occurred 15-60 minutes prior [84]. This supports a hypothesis which suggests 
that CBD metabolites, rather than CBD itself, are responsible for the purported inhibition of 
THC metabolism and elevation of THC concentration in serum and the brain. Furthermore, 
Klein [66] looked into the ostensible involvement of the serotonin 5-HT1A receptor in CBD 
pharmacodynamics after studies reported that the receptor undergoes up-regulated following 
chronic cannabidiol treatment [48]. Despite Zavitsanou’s [48] conjecture not being 
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concurrent with the study’s results, Klein [66] postulates the possibility of the rats having 
been resistant to chronic cannabinoid effects on the 5-HT1A receptor due to the high basal 
density of the receptor in the rats utilised, while Zuardi [82] suggests that factors such as 
rodent strains, CBD administration regime, and variability in psychotomimetic drugs utilised 
could aid elucidation of the experimental discrepancies. 
 
Klein’s (2011) study, which refutes the antipsychotic efficacy of CBD, is somewhat supported 
by a study which scrutinised cannabidiol’s capacity to attenuate behaviours considered 
indicative to positive and negative schizophrenic symptoms (hyperlocomotion, social 
withdrawal, and PPI deficits) in rats subsequent to the induction of a glutamatergic, MK-801-
induced, psychosis [68]. When administered alone CBD was shown to induce detrimental 
PPI deficits as well as increased hyperactivity, though no effect on social behaviour was 
observed. When administered subsequent to the psychotomimetic MK-801, CBD (3, 10, 30 
mg/kg) showed no capacity to attenuate the disruption of PPI and hyperactivity, though it did 
partially attenuate the manifested social withdrawal at 3 & 10 mg/kg. For comparison 
clozapine was also tested, and found to exhibit a capacity to attenuate both MK-801-induced 
hyperlocomotion and social withdrawal (at 3 and 1 mg/kg, respectively), but it only partially 
reduced the PPI disruption of the mice. Based on the results the study concluded with the 
assertion that cannabidiol exhibited primarily prosychotic, along with partial antipsychotic, 
activity.  
 
Having said this, Cannabidiol’s atypical antipsychotic profile and its ostensibly low risk of 
extra-pyramidal side-effects received support from Guimarães’ [85] study, which investigated 
mouse brain activation patterns subsequent to administration of CBD (120 mg/kg), clozapine 
(20 mg/kg), and haloperidol (1 mg/kg) (atypical and typical antipsychotics, respectively). Fos 
immunoreactive neurones (FIr) were used as an indicator of brain activation- for Fos protein 
expression is considered indicative of antipsychotic drug activity. It was found that 
Cannabidiol, haloperidol, and to a lesser extent clozapine, administration resulted in an 
increase in the presence of FIr neurone in a brain region implicated with the pathophysiology 
of schizophrenia, namely the limbic-related nucleus accumbens, while only haloperidol 
induced a significant increase in the motor-related dorsal striatum [85]. Although later studies 
have criticised this study for not investigating other brain structures associated with the 
manifesting of negative symptoms (such as the prefrontal cortex) [86], it nonetheless 
provides a strong biological basis for the hypothesis that CBD possesses an antipsychotic 
profile akin to atypical antipsychotics. 
 
Gururajan [87] set out to assess CBD’s capacity to reverse the MK-801-induced 
hyperactivity, attention-span and social interaction deficits, in a novel testing paradigm 
involving physical separation of Sprague-Dawley rats. Having been assured of the 
paradigm’s validity, it was reported that although both CBD (3 mg/kg) and clozapine (1, 3, 
mg/kg) pre-treatment failed to control the induced attention-span impairments, they both 
successfully mitigated the psychomotor agitation and social investigative behaviour deficits; 
CBD not only normalised, but improved the latter to beyond control levels. This is most 
interesting given that study [68] reported only partial attenuation of MK-801-induced social 
withdrawal in rats following CBD pre-treatment. 
 
Long [88] utilised putative animal models of mania- transmembrane domain neuregulin 1 
mutant (Nrg1 TM HET) mice which exhibit stereotyped psychotic behaviours (namely PPI 
deficits and hyperlocomotion),in addition to diminished 5-HT2A receptor binding density in the 
substantial nigra, so as to test the neuroleptic effects of acute and chronic CBD 
administration. The mice received intraperitoneal vehicle or CBD (1, 50, 100mg/kg) 
  
 
 
International Neuropsychiatric Disease Journal, 1(2):……….., 2013 
 
 
 
 
injections for 21 days, while the behaviour, blood CBD concentrations, and receptor binding 
in specific brain regions relevant to the pathophysiology of schizophrenia were scrutinised. 
The social interaction of mutant mice was selectively increased- in spite of an unaltered 
baseline level of interaction- following long term CBD (50 & 100 mg/kg) treatment. 
Furthermore, an increase in the PPI of mutant mice following acute CBD (100mg/kg) 
administration was observed, showing pharmacology indicative of antipsychotic efficacy; 
though repeat administration lead to a diminishing of this effect, raising questions as to the 
validity of the mutant models’ pharmacodynamics- a doubt the authors dismiss since CBD 
blood concentrations did not differ between genotypes. Despite not having reduced the 
hyperlocomotion of the mutant mice, the wild-type mice were affected by CBD’s anxiolytic 
effects upon repeated administration. As such Long [88] reasoned that Nrg1 modulates both 
the acute and long-term neurobehavioural effects of CBD, for none of the schizophrenia-
related phenotypes were reversed as a result of CBD administration to the mutant mice, 
contradicting ostensible evidence as to CBD’s antipsychotic efficacy.  
 
Spontaneously hypertensive rats (SHR) exhibit positive (hyperlocomotion), and negative 
(deficits in social interaction), stereotyped schizophrenic behaviour- both of which have been 
shown to be ameliorated by typical & atypical, and atypical antipsychotics, respectively [89]. 
As such, Almeida [86] utilised SHRs to scrutinise CBD’s atypical antipsychotic & anxiolytic 
pharmacological profile, and found that none of the acute doses of CBD used (1, 5, 15, 30, 
and 60 mg/kg) had attenuating effects on the SHRs’ stereotyped hyperlocomotion and 
deficits in social interaction- whereas the lowest dose of CBD (1mg/kg) successfully lowered 
the anxiety (and as such increased the social interaction)- of control rats. Almeida [86] 
crucially postulates that one reason for the lack of observed antipsychotic efficacy from CBD 
may be due to a need for SHRs to be exposed to chronic doses of CBD prior to the 
manifestation of antipsychotic effects. 
 
The discrepancy seen within the animal studies has been postulated to arise number of 
factors, including differences in protocols, rodent strains and species, animal models, CBD 
administration regimes, and variability in psychotomimetic drugs utilised [82,86]. 
 
9.  INVESTIGATIONS ON HEALTHY HUMAN SUBJECTS WITH ARTIFICIALLY 
INDUCED PSYCHOSIS 
 
So as to allow CBD to be administered to humans, confirmation of its safety and toxicity 
profile were first required. A crucial early investigation reported no significant detrimental 
clinical, neurological, or psychiatric repercussions to a cohort of healthy volunteers following 
one month of chronic CBD (10-400mg/day dosages) administration [90]. This was 
subsequently confirmed by a study wherein CBD (700mg/day fixed dosage) was 
administered chronically to Huntington’s disease patients [91]. A later investigation found 
that high daily doses of CBD (1,500mg) are well tolerated in humans [92]. Administration of 
CBD through differing routes has also been shown to not induce significant toxic side effects 
in humans [82]. A study engaged in a thorough in vivo and in vitro investigation into the 
safety of CBD administration across a broad range of concentrations found that no notable 
side or toxic effects were induced, other than minor side effects such as the inhibition of 
hepatic drug metabolism [93]. As such these safety studies verified the majority of the 
preclinical animal research findings, which found CBD to be safe for acute and chronic 
administration over a large range of dosages, allowing for the safe progression of the 
research onto human studies.  
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Given the reasonably successful testing of cannabidiol’s safety profile and antipsychotic 
efficacy on animal models with artificially induced psychosis in preclinical trials, studies 
employing human models subsequently gained impetus towards the turn of the millennium. 
One method of assessing the efficacy of neuroleptic drugs in human models involves 
gauging the extent to which they attenuate the subject’s impaired perception of the Binocular 
Depth Inversion (BDI) test illusory image. Psychosis, whether artificially induced or not, 
impairs the perception of the illusory image, and as such the extent to which antipsychotics 
mitigate this impairment is used as a gauge of antipsychotic efficacy [94]. One study tested 
the ability of CBD to attenuate a significant perceptual impairment of the illusory image that 
was induced in healthy volunteers by administration of the psychotomimetic THC 
homologue, Nabilone [95]. The team reported that the impairment was mitigated subsequent 
to cannabidiol (200mg) administration, before going on to propose that CBD may exhibit 
CB1 receptor antagonism- a postulation which was substantiated in a later study [27].  
 
Zuardi [6] utilised healthy volunteers with ketamine-induce psychosis in a double-blind 
crossover procedural study which assessed the extent to which CBD (600mg) attenuated the 
manifest depersonalisation in the nine volunteers which were compared. Separated by a 
week, the subjects sat through two sessions wherein either placebo or CBD was 
administered. After 65 minutes of rest a sub-anaesthetic dose of ketamine was administered 
during the first minute, followed by a maintenance dose after 30 minutes, so as to ensure 
desired serum concentrations. CBD administration was shown to markedly attenuate the 
subsequent ketamine-induced state of depersonalisation in the majority of subjects, as 
assessed in accordance with the Clinician-Administered Dissociative States Scale (CADSS) 
(which gauges factors like depersonalisation, derealisation, and amnesia), affirming the 
hypothesised atypical antipsychotic pharmacological profile of CBD [6]. 
 
Morgan [10] conducted a study investigating the CBD and THC content of 140 individuals’ 
hair and found that three distinct groups were present: THC-only, THC+CBD, and no 
cannabinoid. The study utilised the short form Oxford Liverpool Inventory of Life Experience 
(OLIFE) questionnaires, together with Peter’s Delusion Inventory (PDI), to index the 
individual’s propensity for psychosis manifestation. Morgan [10] discerned that the THC-only 
group exhibited higher levels of delusional thinking and positive schizophrenia symptoms 
than those who fell into the THC+CBD and no cannabinoid groups. The results are 
comparatively tenuous however, for there was an inability to directly infer CBD:THC ratios, 
owing to a lack of comprehension of how cannabinoids are integrated into hair.  
 
Cannabidiol’s capacity to attenuate memory loss and psychotic symptoms was assessed in 
a study which scrutinised the effects of the chosen Cannabis of 134 Cannabis smokers [96]. 
Contrary to the majority of preceding evidence it was found that the levels of cannabidiol 
present in the Cannabis smoked by the subjects did not significantly affect the degree of 
psychotic symptoms exhibited, having observed an elevation in symptoms regardless of 
which of the two groups (high or low CBD) that they fell into. However, they did conclude that 
lower levels of CBD lead to significant hindrance in subject prose recall capability, 
suggesting a mitigating role against THC-induced memory-impairment; the study postulated 
that CB1 receptor antagonism by CBD was behind the effects, in accordance with the 
postulations of a couple of preceding studies [29,95]. 
 
Morgan’s 2011 study [82] set out to assess the effects of acute exposure to smoked 
Cannabis in a naturalistic setting by looking at the ratios of THC and CBD found in the hair of 
120 Cannabis smokers, of which 66 were reported as daily and 54 recreational smokers, 
classifying them in accordance with both the presence and absence of CBD, and high or low 
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concentrations of THC. CBD was found to exhibit protective effects on both positive 
psychotic symptoms and recognition memory impairments in the daily Cannabis users with 
high concentrations of THC in their smoked Cannabis, providing promising support of the 
potential ameliorating effect CBD exhibits to THC’s ostensible psychotomimetic effects [82]. 
 
Hallack [49] utilised ketamine to induce psychosis on 10 healthy volunteers in a double-blind 
procedure so as to gauge the efficacy of CBD (600mg) and placebo in two distinct 
randomised sessions. The subjects were subsequently assessed in accordance with the 
aforementioned Clinician Administered Dissociative State Scale (CADSS) and the Brief 
Psychiatric Rating Scale (BPRS)- which is sub-divided into four factors; positive, negative, 
anxiety/depression, and psychomotor activation- so as to allow assessment of their 
behavioural and subjective effects [49,97-98]. The study reported significantly augmented 
psychomotor activation and a non-significant reduction in the ketamine-induced 
depersonalisation following CBD administration, contrary to evidence suggesting its 
antipsychotic efficacy. Hallack [49] posited that a convoluted mutual interaction of CBD and 
ketamine, on both the glutamatergic and GABAergic signalling pathways, is behind the 
complex pattern of interactive behavioural effects reported in the study. 
 
Schubart [99]amassed and utilised information on the Cannabis use of 1877 Dutch 
individuals who frequently use the same type of Cannabis (>60% of occasions), together 
with subclinical psychiatric experiences by using the Community Assessment of Psychic 
Experiences (CAPE), in a voluntary web-based cross-sectional study. This was done so as 
to allow scrutiny of psychotic experiences in relation to the CBD and THC content of their 
chosen Cannabis variety. A significant inverse relationship between cannabidiol content and 
self-reported positive psychotic experiences was found, though it is important to note that the 
experiences excluded negative symptoms and depression. Despite lacking significant 
legitimacy owing to its reliance on anecdotal evidence, the study nonetheless provides 
support for the notion that CBD exhibits a degree of antipsychotic efficacy.    
 
10. CBD’S ANTIPSYCHOTIC EFFICACY ON PSYCHIATRIC PATIENTS IN A 
CLINICAL SETTING 
 
CBD’s aforesaid lack of toxicity, combined with the promising results from the 
aforementioned studies, allowed for investigations into CBD’s antipsychotic efficacy to 
progress onto testing in psychiatric patients, starting in 1995 with a single-case preclinical 
trial involving a 19 year old woman with schizophrenia who had reported considerable 
hormonal side effects consequent to treatment with conventional antipsychotics. The 
administration of up to 1,500mg/day for 4 weeks resulted in an improvement of her condition 
analogous to the improvement induced by haloperidol, as shown by her cross-criteria Brief 
Psychiatric Rating Scale (BPRS) scores- a  decline in her condition was observed following 
treatment cessations (See figure of patient A in article) [92]. This provided a strong initial 
research foundation from which clinical studies could go on to investigate further, owing to 
the strong supporting evidence for the hypothesised antipsychotic effects of CBD which it 
provides. 
 
A later investigation by the same team from the previously mentioned also looked into 
cannabidiol monotherapy on 3 treatment resistant schizophrenics [100]. The 22-23 year old 
subjects were exposed to 5 days of placebo administration followed by cannabidiol from 
days 6-35 (utilising incremental doses from 40mg/day up to 1280mg/day), then 5 days of 
placebo, before being given 15 days of Olanzapine (atypical antipsychotic). One psychiatrist 
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administered the doses, while two dose-blind psychiatrists screened for adverse effects 
whilst assessing the attenuation of psychotic symptoms, in accordance with BPRS (See 
figures of patients B-D in article) [92]. While only one patient exhibited an improvement to 
their condition, the other two subjects were considered refractory due to their lack of 
response to previous antipsychotic treatment, even to clozapine. Interestingly, two of the 
patients- one who responded to CBD monotherapy and another who didn’t- displayed a 
deterioration of symptoms subsequent to cessation of CBD therapy. Though the study 
reported a weak antipsychotic efficacy, it provided invaluable clarification as to the tolerability 
and toxicity of CBD dosages, with no side effects having been exhibited, even at the highest 
dose administered. 
 
However, a year later a four-week, double-blind, controlled trial comparing the effects of 
CBD monotherapy with the atypical antipsychotic amisulpride in 42 schizophrenic or 
schizophreniform subjects (DSM-IV diagnosed) was reported [101] (as cited in [9] and 
[76,106]. Both courses of treatment resulted in a reduction of reported psychotic symptoms 
after 2-4 weeks, with the only factor having differentiated CBD from amisulpride being lower 
incidences of detrimental side effects (weight gain, extra-pyramidal side symptoms, and 
hyperprolactinaemia). As such this study provided a great deal of support for CBD’s 
hypothesised atypical antipsychotic pharmacology, given its low association with detrimental 
side-effects [100,106]. 
 
The treatment of Parkinson’s disease (PD) patients (up to 30% of whom exhibit incidence of 
psychotic symptoms) poses a great difficulty to psychiatric clinicians for three reasons, (1) 
decreasing doses of anti-Parkinsonian drugs will typically result in exacerbation of motor 
symptoms, (2) the use of typical antipsychotics may lead to augmentation of motor 
symptoms, as previously discussed with regards to extra-pyramidal side effects, and (3) In 
spite of clozapine’s high efficacy in treatment of Parkinson’s, it has the capacity to induce 
detrimental haematological and neurological side effects, amongst others [70,71,76]. As 
such, the necessity for a safe and well-tolerated treatment for psychosis in PD patients lead 
to a pioneering open trial looking into the efficacy, tolerability, and safety of CBD treatment in 
6 PD patients who’d exhibited at least 3 months of psychotic symptoms [102]. A flexible dose 
of CBD, starting at 150mg/day and going up to 400mg/day was used in conjunction with the 
PD patients’ normal treatment. Cannabidiol did not deteriorate motor function, and in fact led 
to a reduction in their symptoms- though this did not achieve statistical significance. 
Furthermore, cannabidiol induced a significant attenuation of psychotic experiences, in 
accordance with the BPRS and Parkinson Psychosis Questionnaire evaluation criteria, with 
no adverse effects reported as a result of treatment. This study not only supports the theory 
that CBD possesses an atypical antipsychotic profile, but it also extends its potential utility to 
the treatment of psychosis in PD patients; though it was acknowledge that further studies 
utilising controlled randomised double-blind assays would be necessary to conclusively 
affirm this. 
 
An investigation [103] asserted, after a 4 week double-blind trial, that CBD was not only 
comparable to amisulpride in its neuroleptic capacity, but also exhibited a markedly superior 
side-effect profile, while also being capable of elevating serum anandamide concentrations. 
This increase in anandamide concentration by CBD is particularly noteworthy, for 
experiments have not only reported elevated anandamide levels in treatment naive and 
acute psychotic patients, but also CBD’s prevention of anandamides’ enzymatic degradation, 
and an inverse relationship between patients’ anandamide concentrations and intensity of 
psychotic symptoms [22,24,104-105]. Subsequently the antipsychotic efficacy of CBD was 
assessed and compared with placebo treatment, so as to test whether CBD (600mg/day) 
  
 
 
International Neuropsychiatric Disease Journal, 1(2):……….., 2013 
 
 
 
 
administration could attenuate antipsychotic symptoms by modulation of serum anandamide 
levels [103]. Each drug was administered for 14 days on a double-blind basis prior to cross-
over; 11 subjects dropped out, one of which was in the CBD treatment group, leaving 18 
treated patients after 28 days. Significant improvements were reported following the first 14 
days of CBD treatment, given that favourable- though not significant- positive and negative 
syndrome scale (PANSS) scores(compared with baseline) were reported. 
 
Following the success of their previous study [103], the team went on to conduct a double-
blind clinical trial on a cohort of 42 schizophrenic patients comparing CBD and amisulpride 
treatment over 4 weeks [106]. It was reported that doses of CBD amounting to 800mg/day 
not only exhibited a markedly superior side-effect profile to amisulpride, but also equal 
antipsychotic efficacy. It was also stated that CBD treatment inhibited fatty acid amide 
hydrolase (FAAH) - the enzyme responsible for the degradation of anandamide- in rat brains 
at a median concentration of 8.6 ± 0.2 µm. This inhibition of FAAH- and as such 
anandamide’s enzymatic break-down- was confirmed in the test subjects, with CBD treated 
individuals having exhibited higher serum anandamide concentrations compared to 
amisulpride treatment. This in turn was shown to result in notable clinical improvements, in 
part owing to the aforementioned statistically significant inverse correlation between the 
patients’ serum anandamide concentrations and psychotic symptoms, which as such 
provides compelling evidence of CBD’s antipsychotic efficacy, as well as a clue as to its 
potential mechanism of action [24,104]. 
 
11. CBD’S ANTIPSYCHOTIC EFFICACY UNDER NEUROIMAGING SCRUTINY 
 
Following years of speculations regarding THC’s purported psychotocatalytic and the largely 
positive- yet still inconclusive- literature detailing experiments into the antipsychotic efficacy 
of CBD, studies utilising functional magnetic resonance imaging (fMRI) started to emerge in 
the past 5 years. 
 
The purpose of the emerging studies was to analyse the behaviour of subjects during tasks 
and their responses to stimuli following the administration of CBD (600mg), or THC (10mg), 
or placebo, and how these correlated with the regional brain activation of a 15 healthy man 
cohort; although the paradigm largely remains fixed throughout the studies, a small number 
of the studies are slightly different, in which case it is explicitly stated. Winton-Brown’s paper 
[107] explains the rationale behind the fixed oral dosages of THC and CBD utilised for the 
fMRI studies, stating that previous research has reported that they induce an effect on the 
regional brain function while avoiding the induction of severe detrimental psychiatric, 
physical, and toxic effects. Despite admitting that a larger cohort may provide greater insight 
into the effects that THC and CBD have on regional brain activation, Borgwardt [108] and 
some of the subsequent studies ward off criticism of unsuitably small cohorts, citing logistical 
difficulties, and Friston’s [109] analysis into what cohort size constitutes a study, as 
justification [110]. 
 
The association between the behaviour and the neuroimaging results would as such allow 
for inference as to the place, and mechanism of action behind CBD and THC (if CBD really 
attenuates the psychotic symptoms induced by THC administration, then are the 
antagonistic effects observed in the same brain regions?). With the exception of the tasks 
undertaken by the subjects all of the neuroimaging experiments that have emerged share a 
common paradigm design (double-blind randomized, cross-over, fMRI, CBD vs THC vs 
placebo paradigm) [65,82,107-108,110-111]. 
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Borgwardt [108] lead the first 3-session double-blind pseudo-randomized cross-over fMRI 
study to analyse the effect of THC, CBD, or placebo treatment on the behaviour and 
associated regional brain activation in healthy individuals. The cohort’s performance in a 
motor inhibition related (Go/No-Go) task was scrutinized, alongside their blood oxygen level 
dependency (BOLD) response. Although there were higher left/right errors following THC 
and CBD treatment, there was no significant inhibition error or reaction time differences 
found to exist between the 3 treatments- the authors postulate that this lack of drug effect on 
task inhibition may possibly be down to a ceiling effect which manifests as a result of the 
utilised task paradigm having reasonably long interstimulus intervals (ISI). The fMRI data 
revealed that- when compared with the placebo treatment- THC administration resulted in 
activation of the right inferior frontal and anterior cingulate gyrus, which, as predicted by the 
authors [108], suggests that THC modulated activity in brain regions responsible for 
mediating response inhibition and motor control. In contrast, CBD administration induced 
deactivation of the left temporal cortex and insula, which aren’t usually association with 
mediation of response inhibition; the authors are quick to indicate that the effects on regional 
brain activation bore no relation to changes in the individual’s psychotic symptoms, 
intoxication, sedation, or anxiety [108]. 
 
The second neuroimaging study which utilise the BOLD fMRI paradigm to emerge was 
Fusar-Poli’s [110], who set out to assess the regional brain activation and autonomic 
anxiety-related electrodermal activity (skin conductance response [SCR]; though objective 
and subjective gauges were utilised in conjunction with this paradigm) of 15 healthy subjects 
during emotional processing of fearful faces while under the effects of either THC, CBD, or 
placebo. As aforementioned, this experiment was of a double-blind, randomized, cross-over 
design. The results showed activation of frontal and parietal areas subsequent to THC 
administration, which was accompanied by an increase in sedation, psychotic symptoms, 
intoxication, and anxiety (SCR fluctuations) [110]. On the other hand CBD administrations 
lead to a suppression of the BOLD signal in the amygdala, and the anterior & posterior 
cingulate cortex of the subjects, which was confirmed by single-photon emission tomography 
(PET). As explained by the authors, the suppression of a BOLD signal in these limbic and 
paralimbic regions were concurrent with- and may help explain- the anxiolytic effect and 
suppression of SCR fluctuations observed following CBD administration [110].  
 
Since preceding studies have suggested that anxiogenic situations may result in the release 
of anandamide from the amygdala, Fusar-Poli [110] reasons that anandamide may in turn 
regulate emotional states and anxiety by modulating the output of the amygdala to other 
brain regions [112-114]. Since CBD has been shown to reduce the enzymatic degradation of 
anandamide, the hypothesised augmentation of anandamide concentrations by CBD is as 
such implicated as a potential mechanism from which CBD’s antipsychotic pharmacology 
arises [22,24,105-106]. 
 
In a pioneering study Bhattacharyya [65] firstly sought to elucidate the opposing effects of 
THC and CBD on regional brain activation, before going on to investigate the attenuating 
effect CBD pre-treatment has on THC-induced acute psychotic symptoms. The first 
paradigm was tested on 15 men during the viewing of fearful faces, as well as performance 
of a verbal memory, response inhibition, and sensory processing task on 3 separate pseudo-
randomized occasions. THC and CBD were found to induce opposing regional brain 
activation patterns relative to placebo in the striatum, hippocampus, amygdala, superior 
temporal cortex, and occipital cortex (during the verbal recall, response inhibition, viewing of 
fearful faces, speech listening, and visual processing tasks, respectively).  
The second part of the study (pseudo-randomized, double-blind, repeated measures, within-
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subject design) utilised 6 healthy volunteers on 2 separate sessions, in which CBD (5mg), or 
placebo, was administered intravenously (IV) over 5 minutes, prior to a 5 minute 
administration of IV THC (1.25mg) - the manifest positive psychotic symptoms being 
measured in accordance with PANSS at baseline, 30, and 90 minutes post-THC. Of the 6 
subjects, 3 experienced psychotic symptoms following THC administration subsequent to 
placebo pre-treatment, and these 3 subjects all exhibited an attenuation of these manifest 
symptoms 30 minutes after CBD pre-treatment & THC administration, as reflected by a 
decrease in their mean PANSS scores. In all the participants’ PANSS scores shown that 
THC-induced psychotic symptoms were significantly lower following CBD pre-treatment, 
compared to placebo pre-treatment. As such, this second experiment provides not only 
strong evidence in support of the postulated neuroleptic efficacy of CBD (given its 
attenuation of THC-induced psychotic symptoms), but also support for the hypothesis that 
the antagonistic action of the two cannabinoids on regional brain activation may be behind 
CBD’s antipsychotic effect. Bhattacharyya [65] also goes so far as to postulate potential 
pharmacodynamic mechanisms underlying its pharmacological profile. These postulations 
include the aforementioned anandamide hydrolysis and reuptake inhibition hypothesis, as 
well as CB1 receptor antagonism (for the opposing effects of THC and CBD on brain regions 
are consistent with the distribution of CB1 receptors).  
 
Winton-Brown [107] set out to further the line of inquiry generated by the aforementioned 
neuroimaging studies by assessing the effects of THC (10mg) and CBD (600mg) on sensory 
cortices. This was achieved by fMRI scans during auditory processing (i.e., gauged during 
passive listening to words by the volunteer) and visual processing (i.e., evaluated during the 
viewing of a “radial visual checkerboard in alternating blocks”). The experiment was carried 
out on 14 volunteers on 3 separate occasions in a double-blinded pseudo-randomized 
crossover designed study, with their anxiety and psychotic phenomena (PANSS) having 
been measured prior to, after, and post, fMRI scanning. While CBD was found to induce no 
notable symptomatic effects, THC resulted in the increase in the subject’s anxiety, 
intoxication, and positive psychotic symptoms.  
 
During the visual processing paradigm THC both increased (in the lingual, fusiform, and 
middle occipital gyri) and decreased (in areas activated under placebo, primarily in the 
extrastriate visual cortex) activation in different visual areas relative to placebo [107]. The 
increase in activation across the visual cortex following THC administration, relative to 
placebo, was found to be correlated and concomitant to the increase in psychotic symptoms, 
and as such PANSS scores- though this trend was found to be statistically insignificant. In 
addition, CBD administration solely increased regional brain activation relative to placebo in 
areas such as the right occipital lobe, cuneus, middle & inferior occipital gyri, and the lingual 
gyrus [107]. When the effects of THC and CBD administration were contrasted a mixed 
effect on the cerebellum was found, while THC was found to activate the left lingual and 
middle occipital gyri, and attenuate activation of widespread occipital regions, bilaterally, 
relative to CBD. 
 
Furthermore, the auditory test paradigm revealed that THC administration resulted in a 
decrease in the activation of the bilateral temporal cortices (relative to placebo), while CBD 
promoted activation in the right temporal cortex [107]. When contrasted, the two substances 
exerted opposing effects- attenuative from THC, excitatory from CBD- on the right posterior 
superior temportal gyrus (the right-sided Wernicke’s area homolog) during auditory 
processing, which just so happens to correlate with the effect THC had on manifesting 
psychotic symptoms. The attenuation of the right temporal cluster induced by THC 
administration, relative to placebo, was found to be concomitant and correlated to the 
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subjects’ increase in psychotic symptoms as measured by their significant PANSS score 
increases [107]. As such, this study affirms the belief that THC and CBD have distinct 
effects- at times in opposing directions- on regional brain activation patterns. Thus, given the 
statistically significant increase in psychotic symptoms that was observed following THC 
administration during the auditory test paradigm, indirect support can be inferred to the 
postulated antipsychotic efficacy of CBD, especially given the study’s crucial scrutiny of how 
the induction of psychotic symptoms correlate with the effects of THC and CBD on sensory 
cortices. 
 
A year following the publication of Winton-Brown’s [107] positive findings, Bhattacharyya’s 
[115] study emerged, which sought to investigate the effects of THC and CBD on regional 
brain function during attentional salience processing task. Salience has been a pertinent 
gauge of psychotic symptoms since evidence emerged that the elevation of dopaminergic 
activity in the striatum has become associated with increased salience attribution to 
insignificant stimuli; this became affirmed by studies ascribing abnormal salience and striatal 
activation to delusions and schizophrenic patients, respectively [115-119]. Following the 
administration of THC, CBD, or placebo, the 15 subjects were asked to focus their attention 
on the detection of an infrequent (oddball) stimulus within a sequence of frequent (standard) 
stimuli, allowing for assessment of their visuo-spatial attention allocation to salience. The 
study hypothesised that THC administration would result in a disruption of the subject’s 
salience processing, leading to swifter responses to standard stimuli (relative to oddball 
stimuli), owing to altered stimulation of the prefrontal cortex, medial temporal cortex, and 
striatum- brain regions which had previously been implicated with the processing of salience 
by earlier studies which utilised similar paradigms [114-115]. While exhibiting augmentative 
effects in the prefrontal cortex, the administration of THC also lead to suppressed activation 
of the hippocampus and dorsal striatum. The suppressive effect of THC on the dorsal 
striatum was reported to be negatively correlated with both the severity of the cohort’s 
psychotic symptoms and the effect on their salience response latency, which was disrupted 
in accordance with the aforementioned hypothesis. Furthermore, as predicted, CBD resulted 
in an opposing task-related activation pattern to THC, when compared to placebo; 
augmentation of striatal and hippocampal activation was reported in conjunction with 
inhibition of prefrontal activation. Given that CBD positively influenced salience processing, 
as well as having increased the subjects’ response latency speed for oddball stimuli relative 
to standard stimuli, Bhattacharyya’s [115] research group postulated that CBD may have, 
given consistent evident supporting the notion that CBD has both behavioural and 
neurophysiological effects opposing THC’s, potential for therapeutic use as an antipsychotic. 
 
11.1 Implications of Neuroimaging Studies 
 
As such, the detailed fMRI studies looking into the effects of both THC and CBD, relative to 
placebo, on regional brain activation revealed some integral indications as to the manner in 
which, and crucially the potential mechanism with which CBD exerts its antipsychotic effect. 
The fMRI data showed that CBD and THC had opposing effects, relative to placebo, in a 
number of cerebral areas, including the amygdala, anterior cingulated cortex, cerebellum, 
middle occipital gyrus, right posterior superior temporal gyrus, parahippocampal gyrus, 
prefrontal cortex, and the striatum [65,82,107-108,110,115]. 
 
The identification of specific brain regions in which CBD and THC exert their opposing effect 
is fundamental to the progression of our understanding of both the pharmacodynamics of 
CBD, and pathophysiology of schizophrenia, hence the importance of these neuroimaging 
studies. The studies of Bhattacharyya [114] and Winton-Brown [107] report, for example, 
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that CBD was capable of opposing the reduction in activation induced by THC in the striatum 
and right temporal lobe of the participants during paired associate learning tasks and 
auditory processing, respectively. In these two studies the reduction in regional brain 
activation by THC was reported to be correlated with an increase in the severity of exhibited 
psychotic symptoms- an effect which was not manifest following CBD administration. As 
such we are able to postulate that the ventral striatum is a brain region involved in CBD’s 
pharmacodynamics and resultant neuroleptic efficacy, a theory which is supported by 
studies which implicate the ventral striatum with the pathogenesis of schizophrenia [65,120]. 
 
Similarly, the temporal lobe- the right one of which is considered important in the 
comprehension of metaphorical language and perception of subordinate meaning in 
ambiguous words- has been implicated with psychotic disorders, including auditory 
hallucinations [121-123]. Since schizophrenic patients have been reported to show an 
impairment in their comprehension of figurative language, Bhattacharyya’s [115] study 
becomes all the more pertinent for reporting that a reduction in the activation of the right 
temporal lobe- and increase in psychotic symptom severity- followed THC administration 
during auditory processing [82,124].Thus we can again postulate that- because of THC’s 
reductive effect on the regional brain activation, which is concurrent with an increase in 
psychotic symptoms- the right temporal lobe can be considered an area associated with the 
neuroleptic effects CBD, given this latter substance’s converse effect on brain activation and 
psychotic symptom severity.  
 
As such it can be concluded that the neuroimaging studies strongly suggest that the ventral 
striatum and temporal lobe, which are areas commonly associated with psychosis, are two 
primary brain regions associated with the effects of CBD, which in turn manifests its 
antipsychotic pharmacology, at least in relation to the psychotomimetic effects of THC [82]. 
 
12. RESULTS OF DETAILED INVESTIGATIONS AND SIGNIFICANCE TO 
BRITISH CANNABIS SMOKERS 
 
It is evident that the literature on the antipsychotic efficacy of cannabidiol possesses some 
incongruities and is in need of further clarifying research, in part owing to the lack of explicit 
understanding as to its pharmacodynamics, though it does for the most part appear to 
support the notion that CBD exhibits a pharmacological profile akin to that of atypical 
antipsychotics. 
 
The major repercussion of this body of evidence is that it brings Frisher’s [33] 
aforementioned study (on page 4)and its assertions under enquiry, for the study scrutinised 
the incidences of schizophrenia and psychoses in the years 1996-2005 based upon 3 
aforementioned assertions, and yet found largely torpid and at times declining incidences of 
psychoses. However, since studies [11,34], have reported that the U.K Cannabis street 
market primarily constituted of hashish- which has been reported to contain higher 
concentrations of cannabidiol- prior to c.2000 (Table 1), then it can be proposed that 
Frisher’s [33] years of focus was at fault. As such there is the potential for unacknowledged 
latent repercussions to the U.K’s Cannabis smokers, for it would manifest 20 years on from 
the transition into a sinsemilla (High THC, low CBD) dominated street market (c.2000), 
assuming Frisher’s [33] 1st and 2nd assertions are sound. Given this prospect it can be 
strongly argued that a greater impetus on both exogenous and endogenous cannabinoid 
research is necessary, so as to clarify understanding of both CBD’s pharmacological efficacy 
  
 
 
International Neuropsychiatric Disease Journal, 1(2):……….., 2013 
 
 
 
 
and our presently limited comprehension of its pharmacodynamics, the current 
understanding of which will be briefly outlined subsequently.  
 
Furthermore there is arguable a need for more research to be done into the role of the 
endocannabinoid system is necessary so as to further our understanding of 
neurophysiology, and our comprehension of psychiatric disorders, 
neuropsychopharmacology, and CBD’s pharmacodynamics. 
 
Bhattacharyya [65] uses the preliminary evidence of Zuardi [72] as a foundation to posit the 
possibility that cannabidiol only exhibits antipsychotic potential in patients hitherto afflicted 
with psychosis- though, in light of the large body of evidence supporting the theory that it 
mitigates artificially-induced acute psychotic symptoms in subjects, we have grounds to 
refute this. 
 
13. POSTULATED PHARMACODYNAMICS BEHIND CBD’S ANTIPSYCHOTIC 
PHARMACOLOGY 
 
The literature has produced a wealth of speculations into the prospective pharmacokinetic 
mechanisms behind CBD and its resultant pharmacological properties as is partly to be 
expected, given the plethora of aforementioned therapeutic properties [15,27]. Thus, so as to 
elucidate the array of convoluted postulations, the prominent pharmacokinetic theories 
relating to of CBD’s antipsychotic pharmacology will be subsequently collated from 
prominent fields of CBD research. Most of the studies investigating the mechanisms of CBD 
have been performed In Vitro, and as such their relevance to In Vivo effects are uncertain, 
as rightly pointed out by [82]. He goes on to compellingly justifies this exercise of caution by 
calling attention to the contradiction that arises when CBD is hypothesised to lower the 
endocannabinoid system’s activity by antagonisism of CB1 & CB2 receptor agonists, while 
also being speculated to be capable of inhibiting the metabolism and re-uptake of the 
endocannabinoid anandamide, which would conversely result in an increase, rather than 
decrease, of the endocannabinoid system’s activity.  
 
13.1  Endocannabinoid System Interaction: Cannabinoid CB1 & CB2 Receptor 
(CB1/2R) Activity 
 
As previously stated, CBD was initially believed to have lacked pharmacological properties 
due to early research reporting a lack of CB receptor binding affinity. CBD has subsequently 
been shown to exhibit CB receptor affinity in the micromolar range, comparative to the low 
nanomolar requirement for THC; molecular reconfiguration of CBD’s stereochemistry- from 
its (-) to (+) enantiomer- has been shown to enhance receptor affinity [15,125]. More recent 
studies have surprisingly reported that CBD exhibits antagonistic interaction with both CB1 
and CB2 receptor at lower than expected concentrations. The research showed that CBD 
had an unexpectedly high antagonistic capacity to the agonists of mouse whole-brain cells 
(CB1 receptors) and Chinese hamster ovary cell membranes which were transfected with 
human CB2 receptors; they reported ostensible KB values in the low nanomolar range [29-
30]. Furthermore, Pertwee [15] has speculated that the unexpected nature of CBD’s 
antagonistic action raises the prospect of this antagonism being of a non-competitive nature. 
Since Bhattacharyya’s [65] study found that CBD-THC antagonism occurred in regional brain 
areas which were correlate to CB1 receptor distribution-and given that THC and other 
exogenous CB1R agonists have been shown to both induce psychotic symptoms in healthy 
individuals and exacerbation of psychotic symptoms in schizophrenic patients- one may 
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postulate that CBD’s antipsychotic efficacy is owed to its CB1R antagonism [82,126-128]. 
Having said this, a large number of schizophrenic patients have been used to test the 
antipsychotic effects gained from a CB1R antagonist (SR141716), which yielded no positive 
support [129]. 
 
13.2 Endocannabinoid System Interaction: Inhibition of Anandamide 
Enzymatic Hydrolysis and Reuptake 
 
Anandamide levels have been found to be up to eight-fold greater in treatment-naive and 
psychiatric patients who are subject to treatment with atypical antipsychotics, whereas 
healthy individuals, patient with dementia,  and patients treated with typical antipsychotics 
did not exhibit this elevation [22,24,82,104-106,130]. The Studies that have reported this 
have also proposed that this elevation in anandamide- given its inverse correlation with 
psychotic symptoms- is a compensatory adaption to the state of psychosis, inferring that it 
potentially acts as an endogenous antipsychotic, released by the body in an attempt to 
attenuate psychosis onset. This hypothesis is supported by Koethe’s [131] study, which 
reported an increased in time taken to reach a state of frank psychosis in patients with 
elevated anandamide concentrations. Seeing as CBD has been shown to prevent 
anandamide’s enzymatic degradation by fatty acid amide hydrolase (FAAH), while also 
preventing its reuptake, it could be reasoned that this- in conjunction with research reporting 
an inverse relationship between anandamide serum concentration and psychotic symptoms- 
is a potential mechanism of action behind CBD’s antipsychotic efficacy [22,24,103,105-106]. 
Cannabidiol’s capacity to prevent degradation and uptake of anandamide was found to be 
augmented by stereochemistry reconfiguration to its (+) enantiomer [15,125]. 
 
In his literature review Zuardi [82] rightly tackles the major uncertainty which accompanies 
the postulation of anandamide playing a role in CBD’s neuroleptic effect- that of the neuronal 
circuitry involved. His postulation is centred on the notion of anandamide-related 
endocannabinoid regulation of the major brain areas understood to be associated with the 
pathophysiology of schizophrenia, namely the ventral tegmental area, nucleus accumbens, 
ventral pallidum, mediodorsal thalamic nucleus and the prefrontal cortex [132]. Zuardi’s [82] 
hypothesised neuronal framework which drives anandamide’s role in manifesting CBD-
induced neuroleptic effects is depicted in the article [82], and is explained as such: 
 
Supersensitive dopaminergic receptor response in the nucleus accumbens of rodents with 
artificially-induced psychosis have been reported, which studies have shown would results in 
the inhibition of both the local medium-spiny GABAergicneurons (which are inhibited by the 
activation of dopamine D2-like receptors [133-134], and constitute ~95% of the nucleus 
accumbens’ neurones), and the medium-spiny associated GABA releasing terminal in the 
ventral pallidum [82,133-136]. As such, Zuardi [82] hypothesises that the release of 
dopamine by projections from the ventral tegmental area (VTA) in the nucleus accumbens 
could alleviate the inhibition of GABAergic neurones in the ventral pallidum, and as such 
result in elevated action of the pallidum-mediodorsal thalamus. Thus there would be a 
resultant reduction in the glutamate release from the pallidum-mediodorsal thalamus to the 
prefrontal cortex, which would manifest in the form of impairment to locomotor activity and 
working memory- symptoms indicative of psychosis [137]. 
 
Zuardi [82] goes on to suggests that endocannabinoids could regulate this system, for the 
endocannabinoid system synthesises anandamide and 2-AG on post-synaptic clefts and 
acting pre-synaptic terminals as part of its role as a negatively-regulating retrograde 
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signalling system [138]. GABA and glutamate neurotransmitters are under particular 
regulatory scrutiny at the hands of the endocannabinoid system, and since CB1 receptors in 
the basal ganglia are located on GABAergic axon terminals to a greater degree than 
glutamatergic ones, one could infer that CBD-induced elevations in anandamide 
concentrations may attenuate the undesirable function of the aforementioned system by 
inhibiting GABA release from the neurones of the ventral pallidum [82,138-139]. 
 
13.3 Endocannabinoid System Interaction: GPR55 Receptor 
 
A developing field of interest in cannabinoid research is the discovery of novel cannabinoid 
receptors, with a breakthrough in the form of successful sequencing and cloning of GPR55- 
a proposed novel human, mouse, and rat cannabinoid receptor- having materialized [140-
141]. The receptor exhibits a similar function and agonistic profile to existing CB receptors, 
and is activated by established endogenous and exogenous CB receptor agonists like 
anandamide and THC, though it is surprisingly antagonised by CBD at lower concentrations 
than that which is considered as required to displace CB1 and CB2 receptor agonists [141].  
 
13.4  The Anti-inflammatory Action of CBD; Vanilloid and Adenosine 
Signalling Pathway Interaction 
 
CBD has also been found to be capable of activating Transient Receptor Vanilloid-1 (TRV1) 
receptors [22,139], which are expressed in brain areas such as the prefrontal cortex, 
amygdala, and hippocampus- areas which have been implicated with states of psychosis 
[142]. The endocannabinoid Anandamide is the most studied putative endovanilloid (EV) and 
TRV1R agonist [82,143]. The agonism of pre-synaptic TRV1R- unlike the activation of CB1 
receptors- results in the facilitation of glutamate release [144]. The role of TRV1R in CBD’s 
antipsychotic efficacy is supported by two aforementioned studies; Guimarães [85] reported 
an increase in neuronal activation in the medial prefrontal cortex and limbic-related nucleus 
accumbens of rats (as measured by cFos immunohistochemistry) following antipsychotic 
doses of CBD (120mg/kg), while Long [82] has reported that CBD’s attenuation of MK-801(a 
non-competitive glutamate antagonist)-induced PPI disruption in rats was prevented by 
TRPV1 antagonists [82].  
 
CBD has also been found to have a mechanism of action analogous to both the natural 
(capsaicin) and synthetic VR1 agonists, though to a weaker degree than the former. The 
Vanilloid VR1 receptor is involved in the mechanism of inflammatory hyperalgesia, though 
stimulation by its natural agonists, capsaicin, results in express paradoxical anti-
inflammatory and analgesic effects (owing to VR1 receptor desensitization) in response to 
nociceptive stimuli, and by causing depletion of sensory vasoactive neuropeptides [22,145]. 
 
Further explanation for cannabidiol’s putative anti-inflammatory activity can be inferred by 
binding studies which report that CBD binds to equilibrative nucleoside transporters; other 
studies report a decrease in [3H] adenosine uptake in the macrophages and microglia of 
murine models [9,146]. 
 
It’s possible that CBD’s potent anti-inflammatory and anti-oxidant/neuroprotective action 
(detailed subsequently) is involved in its ostensible antipsychotic pharmacology, for it is 
thought that the anti-inflammatory and neuroprotective pharmacology of minocycline- a new 
broad-spectrum tetracycline antibiotic used as add-on schizophrenia treatment- may be 
behind its beneficial psychiatric therapeutic effects [9,76,147-148]. 
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13.5 Serotonin 5-HT1a Receptor Agonism 
 
Although little is known about the role the serotonergic system has to play in schizophrenia it 
is hoped that more information will come to light because of the discovery of Aripiprazole, a 
novel antipsychotic which exhibits partial 5-HT1a agonism in conjunction with its 5-HT2a and 
dopamine D2 receptor interaction; it is thought that its serotonergic action plays a role in its 
therapeutic benefit [82,149]. 
 
Cannabidiol’s anxiolytic and antidepressant effects have also been attributed to its agonistic 
relationship to human serotonin 1a (5-HT1a) receptors [22,28,149-153]. Although it would be 
tempting to attribute CBD’s anxiolytic effect to its neuroleptic properties, studies using rodent 
models have shown that the induction an anxiolytic effect (5-20 mg/kg) is far lower than the 
dosages necessary to induce antipsychotic effects (60-120 mg/kg); the former effect dose-
response curve is bell-shaped, rendering larger doses ineffective [74,154-155]. It was 
postulated that rat resistance to chronic cannabinoid effects on the 5-HT1a is due to the high 
basal density of this receptor in rats [66]; could the incongruities observed with CBD’s 
antipsychotic efficacy during the human investigations trials also have emerged as a result of 
varying basal densities of certain receptor groups? 
 
13.6 Neurogenesis 
 
CBD has been shown to be capable of increasing neurogenesis in mice, in a CB1R 
mediated manner [156]. Since the discovery that schizophrenic patients exhibit impaired 
neurogenesis in the hippocampus postulations have emerged which suggest that altered 
neurogenesis may be the cause of the cognitive deficits, and potentially other symptoms, 
observed in schizophrenic patients [157,158]. As such, augmented neurogenesis may be 
one facet of CBD’s action which gives rise to its relatively successful long-term antipsychotic 
efficacy in the clinical trials. 
 
13.7 Anti-oxidant Action 
 
CBD’s ostensible antipsychotic pharmacology may be in part due to its anti-oxidant 
properties.Hampson [159] performed a study wherein it was discovered that CBD (and THC) 
prevents oxidative damage induced by hydrogen peroxide (H2O2) equally or better than 
tocopherol (vitamin E) or ascorbate (vitamin C), and as such may be behind the putative 
neuroprotective/antioxidant properties of cannabidiol [9]. Valvassori’s [81] aforementioned 
study also asserts CBD’s capacity to protect rats against oxidative stress, for it prevented 
dexamphetamine-induced damage in the hippocampus and striatum. 
 
13.8 Peroxisome Proliferator-Activated Receptors (PPARs) Activity 
 
Peroxisome proliferator-activated receptors (PPARs), which are expressed in the nervous 
system and classified into three sub types (α, β, γ), are part of the nuclear receptor 
family[160]. PPARs are ligand-activated transcription factors which fulfil important roles in 
lipid metabolism, hepatic peroximal enzyme expression, insulin sensitivity and glucose 
homeostasis, which arise as a result of their regulating effect on gene expression 
subsequent to binding with sequence-specific promoter elements on target genes [161-162]. 
Although the mechanism behind cannabinoid-PPAR interaction is unclear, a large number of 
cannabinoids have been found to act as PPAR ligands [28,160,163-164]. While anandamide 
has been found to interact with both PPAR-α and PPAR-γ receptors, cannabidiol and THC 
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were found to only interact with PPAR-γ.  Neuroprotective, antioxidant effects have been 
associated with these pathways [28,160,162,165]. THC has been found to exhibit a direct 
neuroprotective action in a human cell culture model of Parkinson’s disease through PPAR-γ 
activity, whilst CBD did not [166]. On the other hand, one study showed that CBD increased 
hippocampal neurogenesis and Amyloid Beta (Aβ)-induced neuroinflammation, while 
another found that CBD attenuated endoplasmic reticulum (ER) stress in oligodendrocyte 
progenitor cells by lowering the concentration of ER apoptotic effectors [167-168]. These 
neuroprotective, antioxidant, effects may, as aforementioned in the previous section, be 
partially responsible for CBD’s (and anandamide’s, as a result of FAAH’s inhibition by CBD) 
antipsychotic effects. 
 
For a highly detailed account of the ostensible pharmacodynamics which may be involved in 
CBD’s antipsychotic properties the reader is advised to consult the papers of Pertwee [15] 
and Izzo [28]. 
 
14. CONCLUSION 
 
To conclude, for nigh on 50 years there has been gradually emergent interest pertaining to 
the abundance of CBD’s pharmaceutical effects (see [15] and [27]), which hold immense 
therapeutic interest and potential utility. Although there is still a wealth of conjecture as to the 
true extent of its pharmacological efficacy and pharmacodynamics, the lack of 
comprehensive understanding ought to fuel the impetus for further studies into CBD and 
cannabinoids generally, in light of the therapeutic potential this once-considered inert 
compound seemingly exhibits. Furthermore, our lack of understanding regarding the crucial 
role of the endocannabinoid system, and its role in psychiatric disorders, means that 
investigations tackling this topic will possess ample heuristic value, given the implications the 
resultant knowledge would have not only on our general understanding of neurophysiology, 
but also our comprehension of neuropharmacology and psychiatric disorders. 
 
The question of CBD’s antipsychotic potential is of particular significance given the 
aforementioned decline of its concentration in U.K. street market Cannabis as of c.2000, 
which was juxtaposed with a significant increase in availability of Cannabis cultivars with 
substantially higher mean concentrations of the ostensibly psychotocatalytic THC. Were 
CBD’s antipsychotic efficacy to be affirmed and established, then, as aforementioned, this 
development has the potential for considerable anthropological ramifications in the form of 
substantial increases in psychosis manifestations and diagnoses in the U.K. If confidence 
was to be placed on research which suggests that the typical precipitation time of psychosis 
is 20 years subsequent to Cannabis use, then this spike would be expected to occur 
between the years 2020-2030.  
 
The research literature largely affirmed the hypothesis that CBD possesses antipsychotic 
efficacy akin to atypical antipsychotics, the significance of which is all the more potent since 
it may have particular advantages in the potential treatment of Parkinson’s disease patients 
with psychosis, given CBD’s comparatively low side and toxiceffects induction. 
 
Significant hypotheses for the mechanisms behind CBD’s antipsychotic efficacy include 
cannabinoid CB receptor antagonism, and inhibition of anandamide hydrolysis & reuptake, 
amongst others. Given the endocannabinoid system’s modulation, and consequent 
interrelation with other neurological pathways (including glutamate, GABA, and serotonin, all 
of which have been independently implicated with psychosis), a potentially fundamental 
discovery pertaining to the aetiology and pathophysiology of psychiatric disorders could 
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result from further investigation into the endocannabinoid system as a whole, as well as the 
effect of exogenous cannabinoid exposure. 
 
Research into cannabinoids and the cannabinoid system is still very much a developing field. 
The encouraging findings detailed, together with our limited understanding of CBD’s 
pharmacodynamics and resultant therapeutic efficacy, should instil a greater impetus for the 
scientific community to clarify our comprehension of this field, particularly given the wide 
prevalence, and immense pharmacological pharmacological potential, of Cannabis- one of 
the worlds’ most ancient and utilised medicinal & recreational drug. 
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